» Authors » Natalia Echeverria

Natalia Echeverria

Explore the profile of Natalia Echeverria including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 136
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Echeverria N, Gambaro F, Beaucourt S, Sonora M, Hernandez N, Cristina J, et al.
Viruses . 2024 Apr; 16(4). PMID: 38675902
Hepatitis C virus (HCV) remains a significant global health challenge, affecting millions of people worldwide, with chronic infection a persistent threat. Despite the advent of direct-acting antivirals (DAAs), challenges in...
2.
Echeverria N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J
World J Hepatol . 2021 Nov; 13(10):1234-1268. PMID: 34786164
Hepatitis C virus (HCV) is responsible for no less than 71 million people chronically infected and is one of the most frequent indications for liver transplantation worldwide. Despite direct-acting antiviral...
3.
Aldunate F, Echeverria N, Chiodi D, Lopez P, Sanchez-Ciceron A, Sonora M, et al.
BMC Infect Dis . 2021 Apr; 21(1):387. PMID: 33902462
Background: Direct-Acting agents (DAAs) target and inhibit essential viral replication proteins. They have revolutionized the treatment of Hepatitis C virus (HCV) infection reaching high levels of sustained virologic response. However,...
4.
Pereira-Gomez M, Fajardo A, Echeverria N, Lopez-Tort F, Perbolianachis P, Costabile A, et al.
J Virol Methods . 2020 Dec; 289:114035. PMID: 33285190
The pandemic caused by SARS-CoV-2 has triggered an extraordinary collapse of healthcare systems and hundred thousand of deaths worldwide. Following the declaration of the outbreak as a Public Health Emergency...
5.
Aldunate F, Echeverria N, Chiodi D, Lopez P, Sanchez-Ciceron A, Fajardo A, et al.
Dis Markers . 2019 Mar; 2019:2520302. PMID: 30867847
No abstract available.
6.
Yu Y, Scheel T, Luna J, Chung H, Nishiuchi E, Scull M, et al.
PLoS Pathog . 2018 Sep; 14(9):e1007303. PMID: 30222761
[This corrects the article DOI: 10.1371/journal.ppat.1006694.].
7.
Aldunate F, Echeverria N, Chiodi D, Lopez P, Sanchez-Ciceron A, Fajardo A, et al.
Dis Markers . 2018 Sep; 2018:2514901. PMID: 30186532
Hepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by the presence of resistance-associated...
8.
Echeverria N, Chiodi D, Lopez P, Sanchez Ciceron A, Angulo J, Lopez-Lastra M, et al.
Virol J . 2018 Mar; 15(1):40. PMID: 29499724
Background: Host single-nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) locus are associated with sustained virological response to antiviral therapy and with spontaneous Hepatitis C Virus (HCV) clearance. Prevalence of...
9.
Yu Y, Scheel T, Luna J, Chung H, Nishiuchi E, Scull M, et al.
PLoS Pathog . 2017 Oct; 13(10):e1006694. PMID: 29084265
Hepatitis C virus (HCV) requires the liver specific micro-RNA (miRNA), miR-122, to replicate. This was considered unique among RNA viruses until recent discoveries of HCV-related hepaciviruses prompting the question of...
10.
Echeverria N, Betancour G, Gambaro F, Hernandez N, Lopez P, Chiodi D, et al.
Virus Res . 2016 Jul; 223:140-6. PMID: 27449600
Hepatitis C virus (HCV) is a major cause of global morbidity and mortality, with an estimated 130-150 million infected individuals worldwide. HCV is a leading cause of chronic liver diseases...